GLOBAL INITIATIVE FOR ASTHMA

Executive Committee (2006)
Paul O'Byrne, M.D., Canada, Chair
Eric D. Bateman, M.D., South Africa
Jean Bousquet, M.D., Ph.D., France
Tim Clark, M.D., U.K.
Pierluigi Paggario, M.D., Italy
Ken Ohta, M.D., Japan
Soren Pedersen, M.D., Denmark
Raj Singh, M.D., India
Manuel Soto-Quiroz, M.D., Costa Rica
Wan Cheng Tan, M.D., Canada

GINA Assembly (2006)
Wan Cheng Tan, M.D., Canada, Chair
GINA Assembly members from 45 countries
(names are listed on website:
http://www.ginasthma.org)
# TABLE OF CONTENTS

**PREFACE** ................................................................................................................... 2

**WHAT IS KNOWN ABOUT ASTHMA?** ................................................................. 4

**DIAGNOSING ASTHMA** ..................................................................................... 6  
Figure 1. Is it Asthma? ......................................................................................... 6

**CLASSIFICATION OF ASTHMA BY LEVEL OF CONTROL** ......................... 8  
Figure 2. Levels of Asthma Control ................................................................. 8

**FOUR COMPONENTS OF ASTHMA CARE** ...................................................... 9

Component 1. **Develop Patient/Family/Doctor Partnership** .............................. 9  
Figure 3. Example of Contents of an Action Plan to Maintain  
Asthma Control ................................................................................................. 10

Component 2. **Identify and Reduce Exposure to Risk Factors** ....................... 11  
Figure 4. Strategies for Avoiding Common Allergens and Pollutants................ 11

Component 3. **Assess, Treat, and Monitor Asthma** ........................................ 12  
Figure 5. Management Approach Based on Control ................................. 14  
Figure 5A. Management Approach Based on Control:  
Children 5 Years and Younger ........................................................................ 14  
Figure 6. Estimated Equipotent Doses of Inhaled  
Glucocorticosteroids for Children .................................................................. 15  
Figure 7. Questions for Monitoring Asthma Care ........................................ 17

Component 4. **Manage Exacerbations** ............................................................ 18  
Figure 8. Severity of Asthma Exacerbations ................................................. 20

**SPECIAL CONSIDERATIONS IN MANAGING ASTHMA** .......................... 22

Appendix A: **Glossary of Asthma Medications - Controllers** .................. 23  
Appendix B: **Glossary of Asthma Medications - Relievers** ......................... 24
Asthma is a major cause of chronic morbidity and mortality throughout the world and there is evidence that its prevalence has increased considerably over the past 20 years, especially in children. The **Global Initiative for Asthma** was created to increase awareness of asthma among health professionals, public health authorities, and the general public, and to improve prevention and management through a concerted worldwide effort. The Initiative prepares scientific reports on asthma, encourages dissemination and implementation of the recommendations, and promotes international collaboration on asthma research.

The **Global Initiative for Asthma** offers a framework to achieve and maintain asthma control for most patients that can be adapted to local health care systems and resources. Educational tools, such as laminated cards, or computer-based learning programs can be prepared that are tailored to these systems and resources.

The **Global Initiative for Asthma** program publications include:

- **Global Strategy for Asthma Management and Prevention (2006).** Scientific information and recommendations for asthma programs.
- **What You and Your Family Can Do About Asthma.** An information booklet for patients and their families.

**Publications are available from [http://www.ginasthma.org](http://www.ginasthma.org).**

This Pocket Guide has been developed from the **Global Strategy for Asthma Management and Prevention (2006).** Technical discussions of asthma, evidence levels, and specific citations from the scientific literature are included in the source document.
Acknowledgements:

Grateful acknowledgement is given for unrestricted educational grants from Altana, AstraZeneca, Boehringer Ingelheim, Chiesi Group, GlaxoSmithKline, Meda Pharma, Merck, Sharp & Dohme, Mitsubishi Pharma, Novartis, and PharmAxis. The generous contributions of these companies assured that the GINA Committees could meet together and publications could be printed for wide distribution. However, the GINA Committee participants are solely responsible for the statements and conclusions in the publications.
WHAT IS KNOWN ABOUT ASTHMA?

Unfortunately... asthma is one of the most common chronic diseases worldwide. The prevalence of asthma symptoms in children varies from 1 to more than 30 percent in different populations and is increasing in most countries, especially among young children.

Fortunately... asthma can be effectively treated and most patients can achieve good control of their disease. When asthma is under control children can:

✓ Avoid troublesome symptoms night and day
✓ Use little or no reliever medication
✓ Have productive, physically active lives
✓ Have (near) normal lung function
✓ Avoid serious attacks

• Asthma causes recurring episodes of wheezing, breathlessness, chest tightness, and coughing, particularly at night or in the early morning.

• Asthma is a chronic inflammatory disorder of the airways. Chronically inflamed airways are hyperresponsive; they become obstructed and airflow is limited (by bronchoconstriction, mucus plugs, and increased inflammation) when airways are exposed to various risk factors.

• Common risk factors for asthma symptoms include exposure to allergens (such as those from house dust mites, animals with fur, cockroaches, pollens, and molds), occupational irritants, tobacco smoke, respiratory (viral) infections, exercise, strong emotional expressions, chemical irritants, and drugs (such as aspirin and beta blockers).

• A stepwise approach to pharmacologic treatment to achieve and maintain control of asthma should take into account the safety of treatment, potential for adverse effects, and the cost of treatment required to achieve control.
• Asthma attacks (or exacerbations) are episodic, but airway inflammation is chronically present.

• For many patients, controller medication must be taken daily to prevent symptoms, improve lung function, and prevent attacks. Reliever medications may occasionally be required to treat acute symptoms such as wheezing, chest tightness, and cough.

• To reach and maintain asthma control requires the development of a partnership between the person with asthma and his or her health care team.

• Asthma is not a cause for shame. Olympic athletes, famous leaders, other celebrities, and ordinary people live successful lives with asthma.
DIAGNOSING ASTHMA

Asthma can often be diagnosed on the basis of a patient’s symptoms and medical history (Figure 1).

<table>
<thead>
<tr>
<th>Figure 1. Is It Asthma?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Consider asthma if any of the following signs or symptoms are present:</td>
</tr>
<tr>
<td>□ Frequent episodes of wheezing—more than once a month</td>
</tr>
<tr>
<td>□ Activity-induced cough or wheeze</td>
</tr>
<tr>
<td>□ Cough particularly at night during periods without viral infections</td>
</tr>
<tr>
<td>□ Absence of seasonal variation in wheeze</td>
</tr>
<tr>
<td>□ Symptoms that persist after age 3</td>
</tr>
<tr>
<td>□ Symptoms occur or worsen in the presence of:</td>
</tr>
<tr>
<td>• Animals with fur</td>
</tr>
<tr>
<td>• Aerosol chemicals</td>
</tr>
<tr>
<td>• Changes in temperature</td>
</tr>
<tr>
<td>• Domestic dust mites</td>
</tr>
<tr>
<td>• Drugs (aspirin, beta blockers)</td>
</tr>
<tr>
<td>• Exercise</td>
</tr>
<tr>
<td>• Pollen</td>
</tr>
<tr>
<td>• Respiratory (viral) infections</td>
</tr>
<tr>
<td>• Smoke</td>
</tr>
<tr>
<td>• Strong emotional expression</td>
</tr>
<tr>
<td>□ The child’s colds repeatedly “go to the chest” or take more than 10 days to clear up</td>
</tr>
<tr>
<td>□ Symptoms improve when asthma medication is given</td>
</tr>
</tbody>
</table>

Measurements of lung function provide an assessment of the severity, reversibility, and variability of airflow limitation, and help confirm the diagnosis of asthma in patients older than 5 years.

**Spirometry** is the preferred method of measuring airflow limitation and its reversibility to establish a diagnosis of asthma.

- An increase in FEV₁ of ≥ 12% (or ≥ 200 ml) after administration of a bronchodilator indicates reversible airflow limitation consistent with asthma. (However, most asthma patients will not exhibit reversibility at each assessment, and repeated testing is advised.)
**Peak expiratory flow (PEF)** measurements can be an important aid in both diagnosis and monitoring of asthma.

- PEF measurements are ideally compared to the patient’s own previous best measurements using his/her own peak flow meter.
- An improvement of $60 \text{ L/min}$ (or $\geq 20\%$ of the pre-bronchodilator PEF) after inhalation of a bronchodilator, or diurnal variation in PEF of more than $20\%$ (with twice-daily readings, more than $10\%$), suggests a diagnosis of asthma.

**Do all children who wheeze have asthma?**

No. Most children who develop wheezing after age 5 have asthma. However, diagnosis of asthma in children 5 years and younger presents a particularly difficult problem. Episodic wheezing and cough are also common in children who do not have asthma, particularly in children younger than age 3. **The younger the child, the greater the likelihood that an alternative diagnosis may explain recurrent wheeze.**

Although there is the possibility of overtreatment, episodes of wheezing may be shortened and reduced in intensity by effective use of anti-inflammatory medications and bronchodilators rather than antibiotics.

Alternative but very rare causes of recurrent wheezing, particularly in early infancy, include chronic rhino-sinusitis, cystic fibrosis, gastroesophageal reflux, recurrent viral lower respiratory tract infections, bronchopulmonary dysplasia, tuberculosis, congenital malformation causing narrowing of the intrathoracic airways, foreign body aspiration, primary ciliary dyskinesia syndrome, immune deficiency, and congenital heart disease.

In children 5 years and younger, the diagnosis of asthma has to be based largely on clinical judgment and an assessment of symptoms and physical findings. A useful method for confirming the diagnosis in this age group is a trial of treatment with short-acting bronchodilators and inhaled glucocorticosteroids. Marked clinical improvement during the treatment and deterioration when treatment is stopped supports a diagnosis of asthma. Children 4 to 5 years old can be taught to use a PEF meter, but to ensure accurate results parental supervision is required.

Other diagnostic considerations in children include:

- Diary cards to record symptoms and PEF (in children older than 5 years) readings are important tools in childhood asthma management.
- Allergy skin tests, or the measurement of specific IgE in serum, can help in the identification of risk factors so that appropriate environmental control measures can be recommended.
CLASSIFICATION OF ASTHMA
BY LEVEL OF CONTROL

Traditionally, the degree of symptoms, airflow limitation, and lung function variability have allowed asthma to be classified by severity (e.g., as Intermittent, Mild Persistent, Moderate Persistent, or Severe Persistent).

However, it is important to recognize that asthma severity involves both the severity of the underlying disease and its responsiveness to treatment. In addition, severity is not an unvarying feature of an individual patient's asthma, but may change over months or years.

Therefore, for ongoing management of asthma, classification of asthma by level of control is more relevant and useful (Figure 2).

---

**Table 2. Levels of Asthma Control**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Controlled (All of the following)</th>
<th>Partly Controlled (Any measure present in any week)</th>
<th>Uncontrolled</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daytime symptoms</td>
<td>None (twice or less/week)</td>
<td>More than twice/week</td>
<td>Three or more features of partly controlled asthma present in any week</td>
</tr>
<tr>
<td>Limitations of activities</td>
<td>None</td>
<td>Any</td>
<td></td>
</tr>
<tr>
<td>Nocturnal symptoms/awakening</td>
<td>None</td>
<td>Any</td>
<td></td>
</tr>
<tr>
<td>Need for reliever/rescue treatment</td>
<td>None (twice or less/week)</td>
<td>More than twice/week</td>
<td></td>
</tr>
<tr>
<td>Lung function (PEF or FEV1)‡</td>
<td>Normal</td>
<td>&lt; 80% predicted or personal best (if known)</td>
<td></td>
</tr>
<tr>
<td>Exacerbations</td>
<td>None</td>
<td>One or more/year*</td>
<td>One in any week†</td>
</tr>
</tbody>
</table>

*Any exacerbation should prompt review of maintenance treatment to ensure that it is adequate.
†By definition, an exacerbation in any week makes that an uncontrolled asthma week.
‡Lung function testing is not reliable for children 5 years and younger.

Examples of validated measures for assessing clinical control of asthma include:
- Asthma Control Test (ACT): http://www.asthmacontrol.com
- Asthma Control Questionnaire (ACQ):
  http://www.qoltech.co.uk/Asthma1.htm
- Asthma Therapy Assessment Questionnaire (ATAQ):
  http://www.ataqinstrument.com
- Asthma Control Scoring System
FOUR COMPONENTS OF ASTHMA CARE

The goal of asthma care is to achieve and maintain control of the clinical manifestations of the disease for prolonged periods. When asthma is controlled, patients can prevent most attacks, avoid troublesome symptoms day and night, and keep physically active.

To reach this goal, four interrelated components of therapy are required:

Component 1. Develop patient/family/doctor partnership
Component 2. Identify and reduce exposure to risk factors
Component 3. Assess, treat, and monitor asthma
Component 4. Manage asthma exacerbations

Component 1: Develop Patient/Family/Doctor Partnership

With the help of everyone on the health care team, children and their families can be actively involved in managing asthma to prevent problems and enable children to live productive, physically active lives. They can learn to:

• Avoid risk factors
• Take medications correctly
• Understand the difference between “controller” and “reliever” medications
• Monitor asthma control status using symptoms and, if available, PEF in children older than 5 years of age
• Recognize signs that asthma is worsening and take action
• Seek medical help as appropriate

Education should be an integral part of all interactions between health care professionals and patients. Using a variety of methods—such as discussions (with a physician, nurse, outreach worker, counselor, or educator), demonstrations, written materials, group classes, video or audio tapes, dramas, and patient support groups—helps reinforce educational messages.
Working together, you and the child and their family/caregiver should prepare a **written personal asthma action plan** that is medically appropriate and practical. A sample asthma plan is shown in **Figure 3**.

Additional self-management plans can be found on several Websites, including:

- http://www.asthma.org.uk
- http://www.nhlbisupport.com/asthma/index.html
- http://www.asthmanz.co.nz

---

**Figure 3. Example of Contents of an Action Plan to Maintain Asthma Control**

**Your Regular Treatment:**
1. Each day take _________________________
2. Before exercise, take _________________________

**WHEN TO INCREASE TREATMENT**

**Assess your level of Asthma Control**
In the past week have you had:

- Daytime asthma symptoms more than 2 times? No Yes
- Activity or exercise limited by asthma? No Yes
- Waking at night because of asthma? No Yes
- The need to use your [rescue medication] more than 2 times? No Yes
- If you are monitoring peak flow, peak flow less than ____? No Yes

If you answered YES to three or more of these questions, your asthma is uncontrolled and you may need to step up your treatment.

**HOW TO INCREASE TREATMENT**

STEP UP your treatment as follows and assess improvement every day:

[Write in next treatment step here]

Maintain this treatment for ________ days [specify number]

**WHEN TO CALL THE DOCTOR/CLINIC**

Call your doctor/clinic: [provide phone numbers]
If you don’t respond in ________ days [specify number]

[Optional lines for additional instruction]

**EMERGENCY/SEVERE LOSS OF CONTROL**

- If you have severe shortness of breath, and can only speak in short sentences,
- If you are having a severe attack of asthma and are frightened,
- If you need your *reliever medication* more than every 4 hours and are not improving.

1. Take 2 to 4 puffs ________ [reliever medication]
2. Take ___mg of ________ [oral glucocorticosteroid]
3. Seek medical help: Go to ____________; Address ____________

   Phone: _____________________

4. Continue to use your ________ [reliever medication] until you are able to get medical help.
Component 2: Identify and Reduce Exposure to Risk Factors

To improve control of asthma and reduce medication needs, patients should take steps to avoid the risk factors that cause their asthma symptoms (Figure 4). However, many asthma patients react to multiple factors that are ubiquitous in the environment, and avoiding some of these factors completely is nearly impossible. Thus, medications to maintain asthma control have an important role because patients are often less sensitive to these risk factors when their asthma is under control.

Physical activity is a common cause of asthma symptoms but patients should not avoid exercise. Symptoms can be prevented by taking a rapid-acting inhaled β₂-agonist before strenuous exercise (a leukotriene modifier or cromone are alternatives).

Children over the age of 3 with severe asthma should be advised to receive an influenza vaccination every year, or at least when vaccination of the general population is advised. However, routine influenza vaccination of children with asthma does not appear to protect them from asthma exacerbations or improve asthma control.

### Figure 4. Strategies for Avoiding Common Allergens and Pollutants

<table>
<thead>
<tr>
<th>Avoidance measures that improve control of asthma and reduce medication needs:</th>
</tr>
</thead>
<tbody>
<tr>
<td>• <strong>Tobacco smoke</strong>: Stay away from tobacco smoke. Patients and parents should not smoke.</td>
</tr>
<tr>
<td>• <strong>Drugs, foods, and additives</strong>: Avoid if they are known to cause symptoms.</td>
</tr>
</tbody>
</table>

Reasonable avoidance measures that can be recommended but have not been shown to have clinical benefit:

- **House dust mites**: Wash bed linens and blankets weekly in hot water and dry in a hot dryer or the sun. Encase pillows and mattresses in air-tight covers. Replace carpets with hard flooring, especially in sleeping rooms. (If possible, use vacuum cleaner with filters. Use acaricides or tannic acid to kill mites—but make sure the patient is not at home when the treatment occurs.)
- **Animals with fur**: Use air filters. (Remove animals from the home, or at least from the sleeping area. Wash the pet.)
- **Cockroaches**: Clean the home thoroughly and often. Use pesticide spray—but make sure the patient is not at home when spraying occurs.
- **Outdoor pollens and mold**: Close windows and doors and remain indoors when pollen and mold counts are highest.
- **Indoor mold**: Reduce dampness in the home; clean any damp areas frequently.
Component 3: Assess, Treat, and Monitor Asthma

The goal of asthma treatment—to achieve and maintain clinical control—can be reached in most patients through a continuous cycle that involves:

- Assessing Asthma Control
- Treating to Achieve Control
- Monitoring to Maintain Control

Assessing Asthma Control

Each patient should be assessed to establish his or her current treatment regimen, adherence to the current regimen, and level of asthma control. A simplified scheme for recognizing controlled, partly controlled, and uncontrolled asthma is provided in Figure 2.

Treating to Achieve Control

For children over age 5, each patient is assigned to one of the treatment “steps” (Figure 5).

At each treatment step, reliever medication should be provided for quick relief of symptoms as needed. (However, be aware of how much reliever medication the patient is using—regular or increased use indicates that asthma is not well controlled.)

At Steps 2 through 5, patients also require one or more regular controller medications, which keep symptoms and attacks from starting. Inhaled glucocorticosteroids (Figure 6) are the most effective controller medications currently available.

For most patients newly diagnosed with asthma or not yet on medication, treatment should be started at Step 2 (or if the patient is very symptomatic, at Step 3). If asthma is not controlled on the current treatment regimen, treatment should be stepped up until control is achieved.

For children age 5 and younger, a low-dose inhaled glucocorticosteroid is the recommended initial controller treatment (Figure 5A). If this treatment does not control symptoms, an increase in the glucocorticosteroid dose is the best option.
A variety of controller (Appendix A) and reliever (Appendix B) medications for asthma are available. The recommended treatments are guidelines only. Local resources and individual patient circumstances should determine the specific therapy prescribed for each patient.

**Inhaled medications** are preferred because they deliver drugs directly to the airways where they are needed, resulting in potent therapeutic effects with fewer systemic side effects.

- Devices available to deliver inhaled medication include pressurized metered-dose inhalers (pMDIs), breath-actuated MDIs, dry powder inhalers (DPIs), and nebulizers. Spacer (or valved holding-chamber) devices make inhalers easier to use and reduce systemic absorption and side effects of inhaled glucocorticosteroids.

- Teach children and their parents how to use inhaler devices. Different devices need different inhalation techniques.
  - Give demonstrations and illustrated instructions.
  - Ask patients to show their technique at every visit.
  - Information about use of various inhaler devices is found on the GINA Website.

- For each child, select the most appropriate device. In general:
  - Children younger than 4 years of age should use a pMDI plus a spacer with face mask, or a nebulizer with face mask.
  - Children aged 4 to 6 years should use a pMDI plus a spacer with mouthpiece, a DPI, or, if necessary, a nebulizer with face mask.
  - For children using spacers, the spacer must fit the inhaler.
  - Children of any age over 6 years who have difficulty using pMDIs should use a pMDI with a spacer, a breath-actuated inhaler, a DPI, or a nebulizer. DPIs require an inspiratory effort that may be difficult to achieve during severe attacks.
  - Children who are having severe attacks should use a pMDI with a spacer or a nebulizer.
  - Particularly among children under age 5, inhaler techniques may be poor and should be monitored closely.
The available literature on treatment of asthma in children 5 years and younger precludes detailed treatment recommendations. The best documented treatment to control asthma in these age groups is inhaled glucocorticosteroids and at Step 2, a low-dose inhaled glucocorticosteroid is recommended as the initial controller treatment. Equivalent doses of inhaled glucocorticosteroids, some of which may be given as a single daily dose, are provided in Figure 6.
**Figure 6. Estimated Equipotent Doses† of Inhaled Glucocorticosteroids for Children**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Low Daily dose (µg)</th>
<th>Medium Daily dose (µg)</th>
<th>High Daily dose (µg)‡</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beclomethasone dipropionate</td>
<td>100-200</td>
<td>&gt;200-400</td>
<td>&gt;400</td>
</tr>
<tr>
<td>Budesonide*</td>
<td>100-200</td>
<td>&gt;200-400</td>
<td>&gt;400</td>
</tr>
<tr>
<td>Budesonide-Neb Inhalation suspension</td>
<td>250-500</td>
<td>&gt;500-1000</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>Ciclesonide*</td>
<td>80-160</td>
<td>&gt;160-320</td>
<td>&gt;320</td>
</tr>
<tr>
<td>Flunisolide</td>
<td>500-750</td>
<td>&gt;750-1250</td>
<td>&gt;1250</td>
</tr>
<tr>
<td>Fluticasone</td>
<td>100-200</td>
<td>&gt;200-500</td>
<td>&gt;500</td>
</tr>
<tr>
<td>Mometasone furoate*</td>
<td>100-200</td>
<td>&gt;200-400</td>
<td>&gt;400</td>
</tr>
<tr>
<td>Triamcinolone acetonide</td>
<td>400-800</td>
<td>&gt;800-1200</td>
<td>&gt;1200</td>
</tr>
</tbody>
</table>

† Comparisons based on efficacy data.
‡ Patients considered for high daily doses except for short periods should be referred to a specialist for assessment to consider alternative combinations of controllers. Maximum recommended doses are arbitrary but with prolonged use are associated with increased risk of systemic side effects.

*Approved for once-daily dosing in mild patients.

Additional Notes:

- The most important determinant of appropriate dosing is the clinician’s judgment of the patient’s response to therapy. The clinician must monitor the patient’s response in terms of clinical control and adjust the dose accordingly. Once control of asthma is achieved, the dose of medication should be carefully titrated to the minimum dose required to maintain control, thus reducing the potential for adverse effects.

- Designation of low, medium, and high doses is provided from manufacturers’ recommendations where possible. Clear demonstration of dose-response relationships is seldom provided or available. The principle is therefore to establish the minimum effective controlling dose in each patient, as higher doses may not be more effective and are likely to be associated with greater potential for adverse effects.

- As CFC preparations are taken from the market, medication inserts for HFA preparations should be carefully reviewed by the clinician for the correct equivalent dosage.
Monitoring to Maintain Control

Ongoing monitoring is essential to maintain control and establish the lowest step and dose of treatment to minimize cost and maximize safety.

Typically, patients should be seen one to three months after the initial visit, and every three months thereafter. After an exacerbation, follow-up should be offered within two weeks to one month.

At each visit, ask the questions listed in Figure 7.

Adjusting medication:

- If asthma is *not controlled* on the current treatment regimen, **step up** treatment. Generally, improvement should be seen within 1 month. But first review the patient’s medication technique, compliance, and avoidance of risk factors.
- If asthma is **partly controlled**, **consider stepping up** treatment, depending on whether more effective options are available, safety and cost of possible treatment options, and the patient’s satisfaction with the level of control achieved.
- If control is **maintained** for at least 3 months, **step down** with a gradual, stepwise reduction in treatment. The goal is to decrease treatment to the least medication necessary to maintain control.

Monitoring is still necessary even after control is achieved, as asthma is a variable disease; treatment has to be adjusted periodically in response to loss of control as indicated by worsening symptoms or the development of an exacerbation.

Consult with an asthma specialist when other conditions complicate asthma, if the child does not respond to therapy, or if asthma remains uncontrolled with treatment at step 3.
### Figure 7. Questions for Monitoring Asthma Care

#### IS THE ASTHMA MANAGEMENT PLAN MEETING EXPECTED GOALS?

**Ask the patient:**
- Has your asthma awakened you at night?
- Have you needed more reliever medications than usual?
- Have you needed any urgent medical care?
- Has your peak flow been below your personal best?
- Are you participating in your usual physical activities?

**Action to consider:**
- Adjust medications and management plan as needed (step up or step down).
- But first, compliance should be assessed.

#### IS THE PATIENT USING INHALERS, SPACER, OR PEAK FLOW METERS CORRECTLY?

**Ask the patient:**
- Please show me how you take your medicine.

**Action to consider:**
- Demonstrate correct technique.
- Have patient demonstrate back.

#### IS THE PATIENT TAKING THE MEDICATIONS AND AVOIDING RISK FACTORS ACCORDING TO THE ASTHMA MANAGEMENT PLAN?

**Ask the patient, for example:**
- So that we may plan therapy, please tell me how often you actually take the medicine.
- What problems have you had following the management plan or taking your medication?
- During the last month, have you ever stopped taking your medicine because you were feeling better?

**Action to consider:**
- Adjust plan to be more practical.
- Problem solve with the patient to overcome barriers to following the plan.

#### DOES THE PATIENT HAVE ANY CONCERNS?

**Ask the patient:**
- What concerns might you have about your asthma, medicines, or management plan?

**Action to consider:**
- Provide additional education to relieve concerns and discussion to overcome barriers.
Component 4: Manage Exacerbations

Exacerbations of asthma (asthma attacks) are episodes of a progressive increase in shortness of breath, cough, wheezing, or chest tightness, or a combination of these symptoms.

Do not underestimate the severity of an attack; severe asthma attacks may be life threatening.

Children/adolescents at high risk for asthma-related death require closer attention and should be encouraged to seek urgent care early in the course of their exacerbations. These patients include those:

- With a history of near-fatal asthma
- Who have had a hospitalization or emergency visit for asthma within the past year, or prior intubation for asthma
- Who are currently using or have recently stopped using oral glucocorticosteroids
- Who are overdependent on rapid-acting inhaled β₂-agonists
- With a history of psychosocial problems or denial of asthma or its severity
- With a history of noncompliance with asthma medication plan

Patients should immediately seek medical care if...

- The attack is severe (Figure 8):
  - The patient is breathless at rest, is hunched forward, talks in words rather than sentences (infant stops feeding), agitated, drowsy or confused, has bradycardia, or a respiratory rate greater than 30 per minute
  - Wheeze is loud or absent
  - Pulse is greater than: 160/min for infants 120/min for children 1-2 years 110/min for children 2-8 years
  - PEF is less than 60 percent of predicted or personal best even after initial treatment
  - The child is exhausted
- The response to the initial bronchodilator treatment is not prompt and sustained for at least 3 hours
- There is no improvement within 2 to 6 hours after oral glucocorticosteroid treatment is started
- There is further deterioration
Mild attacks, defined by a reduction in peak flow of less than 20%, nocturnal awakening, and increased use of rapid-acting β₂-agonists, can usually be treated at home if the patient is prepared and has a personal asthma management plan that includes action steps.

Moderate attacks may require, and severe attacks usually require, care in a clinic or hospital.

**Asthma attacks require prompt treatment:**

- Oxygen is given at health centers or hospitals if the patient is hypoxemic (achieve O₂ saturation of 95%).
- Inhaled rapid-acting β₂-agonists in adequate doses are essential. (Begin with 2 to 4 puffs every 20 minutes for the first hour; then mild exacerbations will require 2 to 4 puffs every 3 to 4 hours, and moderate exacerbations 6 to 10 puffs every 1 to 2 hours)
- Oral glucocorticosteroids (0.5 to 1 mg of prednisolone/kg or equivalent during a 24-hour period) introduced early in the course of a moderate or severe attack help to reverse the inflammation and speed recovery.
- Methylxanthines are not recommended if used in addition to high doses of inhaled β₂-agonists. However, theophylline can be used if inhaled β₂-agonists are not available. If the patient is already taking theophylline on a daily basis, serum concentration should be measured before adding short-acting theophylline.

Therapies **not recommended** for treating attacks include:

- Sedatives (strictly avoid).
- Mucolytic drugs (may worsen cough).
- Chest physical therapy/physiotherapy (may increase patient discomfort).
- Hydration with large volumes of fluid for adults and older children (may be necessary for younger children and infants).
- Antibiotics (do not treat attacks but are indicated for patients who also have pneumonia or bacterial infection such as sinusitis).
- Epinephrine (adrenaline) may be indicated for acute treatment of anaphylaxis and angioedema but is not indicated during asthma attacks.
- Intravenous magnesium sulphate has not been studied in young children.
Hypercapnia (hypoventilation) develops more readily in young children than in adolescents.

*Note: The presence of several parameters, but not necessarily all, indicates the general classification of the exacerbation.
†Note: Kilopascals are also used internationally, conversion would be appropriate in this regard.

### Figure 8. Severity of Asthma Exacerbations*

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Mild</th>
<th>Moderate</th>
<th>Severe</th>
<th>Respiratory arrest imminent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breathless</td>
<td>Walking</td>
<td>Talking infant - softer, shorter cry; difficulty feeding</td>
<td>At rest infant stops feeding</td>
<td>Hunched forward</td>
</tr>
<tr>
<td></td>
<td>Can lie down</td>
<td>Prefer sitting</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Talks in</td>
<td>Sentences</td>
<td>Phrases</td>
<td>Words</td>
<td></td>
</tr>
<tr>
<td>Alertness</td>
<td>May be agitated</td>
<td>Usually agitated</td>
<td>Usually agitated</td>
<td>Drowsy or confused</td>
</tr>
<tr>
<td>Respiratory rate</td>
<td>Increased</td>
<td>Increased</td>
<td>Often &gt; 30/min</td>
<td></td>
</tr>
</tbody>
</table>

**Normal rates of breathing in awake children:**

<table>
<thead>
<tr>
<th>Age</th>
<th>Normal rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 2 months</td>
<td>&lt; 60/ min</td>
</tr>
<tr>
<td>2-12 months</td>
<td>&lt; 50/ min</td>
</tr>
<tr>
<td>1-5 years</td>
<td>&lt; 40/ min</td>
</tr>
<tr>
<td>6-8 years</td>
<td>&lt; 30/ min</td>
</tr>
</tbody>
</table>

**Accessory muscles and suprasternal retractions:**

<table>
<thead>
<tr>
<th></th>
<th>Usually not</th>
<th>Usually</th>
<th>Usually</th>
<th>Paradoxical thoraco-abdominal movement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wheeze</td>
<td>Moderate, often only and expiratory</td>
<td>Loud</td>
<td>Usually loud</td>
<td>Absence of wheeze</td>
</tr>
</tbody>
</table>

**Pulse/min.**

<table>
<thead>
<tr>
<th></th>
<th>&lt; 100</th>
<th>100-120</th>
<th>&gt; 120</th>
<th>Bradycardia</th>
</tr>
</thead>
</table>

**Guide to limits of normal pulse rate in children:**

<table>
<thead>
<tr>
<th>Infants</th>
<th>Normal rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preschool</td>
<td>&lt;160/ min</td>
</tr>
<tr>
<td>School age</td>
<td>&lt;120/ min</td>
</tr>
<tr>
<td>2-8 years</td>
<td>&lt;110/ min</td>
</tr>
</tbody>
</table>

**Pulsus paradoxus**

<table>
<thead>
<tr>
<th>Over 80%</th>
<th>Approx. 60-80%</th>
<th>&lt; 60% predicted or personal best (&lt; 100 L/min adolescents) or response lasts &lt; 2 hrs</th>
<th>Absence suggests respiratory muscle fatigue</th>
</tr>
</thead>
<tbody>
<tr>
<td>Absent</td>
<td>May be present</td>
<td>&gt; 25 mm Hg (adult) 20-40 mm Hg (child)</td>
<td></td>
</tr>
<tr>
<td>&lt; 10 mm Hg</td>
<td>10-25 mm Hg</td>
<td>&lt; 60 mm Hg Possible cyanosis &gt; 45 mm Hg Possible respiratory failure (see text)</td>
<td></td>
</tr>
</tbody>
</table>

**PEF after initial bronchodilator**

<table>
<thead>
<tr>
<th>Over 80%</th>
<th>Normal Test not usually necessary</th>
<th>&lt; 45 mm Hg</th>
<th>&gt; 60 mm Hg</th>
<th>&lt; 60 mm Hg Possible cyanosis &gt; 45 mm Hg Possible respiratory failure (see text)</th>
</tr>
</thead>
<tbody>
<tr>
<td>% predicted or personal best</td>
<td>45 mm Hg</td>
<td>&gt; 60 mm Hg</td>
<td>PaCO₂ (on air)</td>
<td>45 mm Hg</td>
</tr>
<tr>
<td>&lt; 10 mm Hg</td>
<td>10-25 mm Hg</td>
<td>&gt; 25 mm Hg</td>
<td>PaCO₂ (on air)</td>
<td>20-40 mm Hg</td>
</tr>
<tr>
<td>&lt; 10 mm Hg</td>
<td>10-25 mm Hg</td>
<td>&gt; 25 mm Hg</td>
<td>PaCO₂ (on air)</td>
<td>20-40 mm Hg</td>
</tr>
</tbody>
</table>

**SaO₂% (on air)**

<table>
<thead>
<tr>
<th>&gt; 95%</th>
<th>91-95%</th>
<th>&lt; 90%</th>
</tr>
</thead>
</table>

*Hypercapnia (hypoventilation) develops more readily in young children than in adolescents.*

*Note: The presence of several parameters, but not necessarily all, indicates the general classification of the exacerbation.†Note: Kilopascals are also used internationally, conversion would be appropriate in this regard.*
Monitor Response to Treatment

Evaluate symptoms and, as much as possible, peak flow. In the hospital, also assess oxygen saturation; consider arterial blood gas measurement in patients with suspected hypoventilation, exhaustion, severe distress, or peak flow 30-50 percent predicted.

Follow up:

After the exacerbation is resolved, the factors that precipitated the exacerbation should be identified and strategies for their future avoidance implemented, and the patient’s medication plan reviewed.
Special considerations are required in managing asthma in relation to:

**Surgery.** Airway hyperresponsiveness, airflow limitation, and mucus hypersecretion predispose patients with asthma to intraoperative and postoperative respiratory complications, particularly with thoracic and upper abdominal surgeries. Lung function should be evaluated several days prior to surgery, and a brief course of glucocorticosteroids prescribed if FEV₁ is less than 80% of the patient’s personal best.

**Rhinitis, Sinusitis, and Nasal Polyps.** Rhinitis and asthma often coexist in the same patient, and treatment of rhinitis may improve asthma symptoms. Both acute and chronic sinusitis can worsen asthma, and should be treated. Nasal polyps are associated with asthma and rhinitis, often with aspirin sensitivity and most frequently in adult patients. They are normally quite responsive to topical glucocorticosteroids.

**Respiratory infections.** Respiratory infections provoke wheezing and increased asthma symptoms in many patients. Treatment of an infectious exacerbation follows the same principles as treatment of other exacerbations.

**Gastroesophageal reflux.** Gastroesophageal reflux is nearly three times as prevalent in patients with asthma compared to the general population. Medical management should be given for the relief of reflux symptoms, although this does not consistently improve asthma control.

**Anaphylaxis.** Anaphylaxis is a potentially life-threatening condition that can both mimic and complicate severe asthma. Prompt treatment is crucial and includes oxygen, intramuscular epinephrine, injectable antihistamine, intravenous hydrocortisone, and intravenous fluid.
### Appendix A: Glossary of Asthma Medications - Controllers

<table>
<thead>
<tr>
<th>Name and Also Known As</th>
<th>Usual Doses</th>
<th>Side Effects</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Glucocorticosteroids</strong>&lt;br&gt;Adrenocorticoids&lt;br&gt;Corticosteroids&lt;br&gt;Glucocorticoids</td>
<td><strong>Inhaled:</strong> Beginning dose dependent on asthma control then titrated down over 2-3 months to lowest effective dose once control is achieved.&lt;br&gt;<strong>Tablets or syrups:</strong> For daily control use lowest effective dose 5-40 mg of prednisone equivalent in a.m. or qod.&lt;br&gt;For acute attacks 40-60 mg daily in 1 or 2 divided doses for adolescents or 1-2 mg/kg daily in children.</td>
<td><strong>Inhaled:</strong> High daily doses may be associated with skin thinning and bruises, and rarely adrenal suppression. Local side effects are hoarseness and oropharyngeal candidiasis. Low to medium doses have produced minor growth delay or suppression (av. 1cm) in children. A attainment of predicted adult height does not appear to be affected.&lt;br&gt;<strong>Tablets or syrups:</strong> Used long term, may lead to osteoporosis, hypertension, diabetes, cataracts, adrenal suppression, growth suppression, obesity, skin thinning or muscle weakness. Consider coexisting conditions that could be worsened by oral glucocorticosteroids, e.g. herpes virus infections, Varicella, tuberculosis, hypertension, diabetes and osteoporosis</td>
<td><strong>Inhaled:</strong> Potential but small risk of side effects is well balanced by efficacy. Valved holding-chambers with MDIs and mouth washing with DPIs after inhalation decrease oral Candidiasis. Preparations not equivalent on per puff or μg basis.&lt;br&gt;<strong>Tablet or syrup:</strong> High long term use: alternate day a.m. dosing produces less toxicity. Short term: 3-10 day “bursts” are effective for gaining prompt control.</td>
</tr>
<tr>
<td><strong>Inhaled (ICS):</strong>&lt;br&gt;Beclomethasone&lt;br&gt;Budesonide&lt;br&gt;Ciclesonide&lt;br&gt;Flunisolide&lt;br&gt;Fluticasone&lt;br&gt;Mometasone&lt;br&gt;Triamcinolone</td>
<td><strong>Tablets or syrups:</strong> hydrocortisone&lt;br&gt;methylprednisolone&lt;br&gt;prednisolone&lt;br&gt;prednisone</td>
<td><strong>Sodium cromoglycate</strong>&lt;br&gt;cromolyn&lt;br&gt;cromones</td>
<td><strong>Nedocromil</strong>&lt;br&gt;cromones</td>
</tr>
</tbody>
</table>
| **Sustained-release Tablets:**<br>Salbutamol (S)<br>Terbutaline (T) | **Inhaled:** DPI-F/S 100, 250, or 500 μg/50 μg 1 inhalation bid.<br>DPI-Sm: 1 inhalation bid.<br>DPI-B/F: 100 or 200 μg/6 μg 1 inhalation bid.<br>DPI-B/F: 80 or 160 μg/ 4.5 μg 2 puffs bid | **Similar to those described above for individual components of the combination** | **In moderate to severe persistent asthma, combination more effective than doubling the ICS dose. Budesonide/formoterol has been approved for adjustable as needed dosing in addition to regular dosing in some countries. Dosing is dependent on level of control. Limited data in children 4-11 yrs No data in children < 4 yrs.** | **Tablet or syrup:** Valued holding-chambers with MDIs and mouth washing with DPIs after inhalation decrease oral Candidiasis. Preparations not equivalent on per puff or μg basis.** | **GINA PED GUIDE 2006 12/12/06 2:49 PM**

---

Table continued...
### Appendix A: Glossary of Asthma Medications - Controllers (continued...)

<table>
<thead>
<tr>
<th>Name and Also Known As</th>
<th>Usual Doses</th>
<th>Side Effects</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sustained-release Theophylline Aminophylline methylxanthine xanthine</td>
<td>Starting dose 10 mg/kg/day with usual 800 mg maximum in 1-2 divided doses</td>
<td>Nausea and vomiting are most common. Serious effects occurring at higher serum concentrations include seizures, tachycardia, and arrhythmias.</td>
<td>Theophylline level monitoring is often required. Absorption and metabolism may be affected by many factors, including febrile illness.</td>
</tr>
<tr>
<td>Antileukotrienes Leukotriene modifiers Montelukast (M) Pranlukast (P) Zafirlukast (Z) Zileuton (Zi)</td>
<td>Adolescents: M 10 mg qhs P 450 mg bid Z 20 mg bid; Zi 600 mg qid. Children: M 5 mg qhs (6-14 y) M 4 mg qhs (2-5 y) Z 10 mg bid (7-11 y).</td>
<td>No specific adverse effects to date at recommended doses. Elevation of liver enzymes with Zafirlukast and Zileuton and limited case reports of reversible hepatitis and hyperbilirubinemia with Zileuton and hepatic failure with Zafirlukast.</td>
<td>Antileukotrienes are most effective for patients with mild persistent asthma. They provide additive benefit when added to ICSs though not as effective as inhaled long-acting β₂-agonists.</td>
</tr>
<tr>
<td>Immunomodulators Omalizumab Anti-IgE</td>
<td>Adolescents: Dose administered subcutaneously every 2 or 4 weeks dependent on weight and IgE concentration</td>
<td>Pain and bruising at injection site (5-20%) and very rarely anaphylaxis (0.1%).</td>
<td>Need to be stored under refrigeration 2-8°C and maximum of 150 mg administered per injection site.</td>
</tr>
</tbody>
</table>

### Appendix B: Glossary of Asthma Medications - Relievers

<table>
<thead>
<tr>
<th>Name and Also Known As</th>
<th>Usual Doses</th>
<th>Side Effects</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Short-acting β₂-agonists Adrenergics β₂-stimulants Sympathomimetics</td>
<td>Differences in potency exist but all products are essentially comparable on a per puff basis. For prn symptomatic use and pretreatment before exercise 2 puffs MDI or 1 inhalation DPI. For asthma attacks 4-8 puffs q2-4h, may administer q20min x 3 with medical supervision or the equivalent of 5 mg salbutamol by nebulizer.</td>
<td>Inhaled: tachycardia, skeletal muscle tremor, headache, and irritability. At very high dose hyperglycemia, hypokalemia. Systemic administration as Tablets or Syrup increases the risk of these side effects.</td>
<td>Drug of choice for acute bronchospasm. Inhaled route has faster onset and is more effective than tablet or syrup. Increasing use, lack of expected effect, or use of &gt; 1 canister a month indicate poor asthma control; adjust long-term therapy accordingly. Use of ≥ 2 canisters per month is associated with an increased risk of a severe, life-threatening asthma attack.</td>
</tr>
<tr>
<td>Anticholinergics Ipratropium bromide (IB) Oxtropium bromide</td>
<td>IB-MDI 4-6 puffs q6h or q20 min in the emergency department. Nebulizer 500 µg q20 min x 3 then q2-4hrs for adolescents and 250-500 µg for children.</td>
<td>Minimal mouth dryness or bad taste in the mouth.</td>
<td>May provide additive effects to β₂-agonist but has slower onset of action. Is an alternative for patients with intolerance for β₂-agonists.</td>
</tr>
<tr>
<td>Short-acting theophylline Aminophylline</td>
<td>7 mg/kg loading dose over 20 min followed by 0.4 mg/kg/hr continuous infusion.</td>
<td>Nausea, vomiting, headache. At higher serum concentrations: seizures, tachycardia, and arrhythmias.</td>
<td>Theophylline level monitoring is required. Obtain serum levels 12 and 24 hours into infusion. Maintain between 10-15 µg/mL.</td>
</tr>
<tr>
<td>Epinephrine/ adrenaline injection</td>
<td>1:1000 solution (1mg/mL). 0.1mg/kg up to 0.3-0.5 mg can give q20min x 3.</td>
<td>Similar, but more significant effects than selective β₂-agonist. In addition: hypertension, fever, vomiting in children and hallucinations.</td>
<td>In general, not recommended for treating asthma attacks if selective β₂-agonists are available.</td>
</tr>
</tbody>
</table>
The Global Initiative for Asthma is supported by educational grants from:

ALTANA Pharma
AstraZeneca
Boehringer Ingelheim
Mitsubishi Pharma Corporation
Chiesi
Novartis
GlaxoSmithKline
Pharmaxis

Visit the GINA Website at www.ginasthma.org